Diabetes:普伐他汀和缬沙坦联合治疗高胆固醇血症效果优于单药治疗

2013-07-24 Diabetes dxy

他汀类药物和血管紧张素Ⅱ1型受体阻断剂能够通过不同机制改善内皮功能紊乱。为评估普伐他汀和缬沙坦单药或联合治疗高胆固醇血症患者的血管和代谢反应,来自韩国嘉川大学吉尔医学中心的Kwang Kon Koh教授及其团队进行了一项研究,该研究发现普伐他汀与其它药物联合,可以安全的使血脂降至目标水平,同时改善高危患者的代谢和心血管表型。该研究结果在线发表于2013年7月17日的《糖尿病》(Diabetes)杂

他汀类药物和血管紧张素Ⅱ1型受体阻断剂能够通过不同机制改善内皮功能紊乱。为评估普伐他汀和缬沙坦单药或联合治疗高胆固醇血症患者的血管和代谢反应,来自韩国嘉川大学吉尔医学中心的Kwang Kon Koh教授及其团队进行了一项研究,该研究发现普伐他汀与其它药物联合,可以安全的使血脂降至目标水平,同时改善高危患者的代谢和心血管表型。该研究结果在线发表于2013年7月17日的《糖尿病》(Diabetes)杂志上。

在该项随机、单盲、安慰剂对照交叉实验中,48例高胆固醇血症患者(23例有代谢综合征)被分为三个治疗组,在每2个月的治疗期内,每天分别接受普伐他汀40mg和安慰剂,或普伐他汀40mg和缬沙坦160mg,或缬沙坦160mg和安慰剂。实验还包含2个洗脱期(每2个月)。

研究发现,联合治疗组与任何一个单药治疗组相比,肱动脉血流介导的舒张功能和C反应蛋白均有更大幅度的改善。更重要的实验结果在于,相对基线测量值,所有三个治疗组的代谢表型均有所改善,患者血浆脂联素水平升高、空腹胰岛素水平下降、并且胰岛素敏感性增加。研究人员第一次在他汀类药物联合试验中发现,与单药治疗相比,普伐他汀联合缬沙坦治疗能以叠加方式升高血浆脂联素水平,降低空腹胰岛素水平,同时改善胰岛素敏感性。

该研究表明,与其它他汀类药物相比,亲水性普伐他汀可能与其它药物联合,在安全有效的降低血脂至目标水平的同时改善高危患者的代谢和心血管表型。


原始出处:
Kwang Kon Koh, MD⇑, Soo Lim, MD, MPH, PhD, Dr.PH¶, Hanul Choi, MD, Yonghee Lee, PhD*, Seung Hwan Han, MD, Kyounghoon Lee, MD, Pyung Chun Oh, MD, Ichiro Sakuma, MD, PhD#, Eak Kyun Shin, MD and Michael J. Quon, MD, PhD+;Combination Pravastatin and Valsartan Treatment have Additive Beneficial Effects to Simultaneously Improve Both Metabolic and Cardiovascular Phenotypes beyond that of Monotherapy with Either Drug In Patients with Primary Hypercholesterolemia;Diabetes July 17, 2013

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687672, encodeId=7cef168e672da, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Wed Apr 09 04:29:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759328, encodeId=5b6c1e59328fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 25 13:29:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901131, encodeId=07b6190113191, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 16 11:29:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945585, encodeId=8b841945585d7, content=<a href='/topic/show?id=97c6599160e' target=_blank style='color:#2F92EE;'>#普伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59916, encryptionId=97c6599160e, topicName=普伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat Oct 05 11:29:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636722, encodeId=a8b91636e226f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 19 01:29:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313618, encodeId=bf431313618a7, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367656, encodeId=b9d7136e656e7, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380008, encodeId=fb18138000837, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1687672, encodeId=7cef168e672da, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Wed Apr 09 04:29:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759328, encodeId=5b6c1e59328fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 25 13:29:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901131, encodeId=07b6190113191, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 16 11:29:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945585, encodeId=8b841945585d7, content=<a href='/topic/show?id=97c6599160e' target=_blank style='color:#2F92EE;'>#普伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59916, encryptionId=97c6599160e, topicName=普伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat Oct 05 11:29:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636722, encodeId=a8b91636e226f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 19 01:29:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313618, encodeId=bf431313618a7, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367656, encodeId=b9d7136e656e7, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380008, encodeId=fb18138000837, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1687672, encodeId=7cef168e672da, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Wed Apr 09 04:29:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759328, encodeId=5b6c1e59328fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 25 13:29:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901131, encodeId=07b6190113191, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 16 11:29:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945585, encodeId=8b841945585d7, content=<a href='/topic/show?id=97c6599160e' target=_blank style='color:#2F92EE;'>#普伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59916, encryptionId=97c6599160e, topicName=普伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat Oct 05 11:29:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636722, encodeId=a8b91636e226f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 19 01:29:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313618, encodeId=bf431313618a7, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367656, encodeId=b9d7136e656e7, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380008, encodeId=fb18138000837, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1687672, encodeId=7cef168e672da, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Wed Apr 09 04:29:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759328, encodeId=5b6c1e59328fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 25 13:29:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901131, encodeId=07b6190113191, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 16 11:29:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945585, encodeId=8b841945585d7, content=<a href='/topic/show?id=97c6599160e' target=_blank style='color:#2F92EE;'>#普伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59916, encryptionId=97c6599160e, topicName=普伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat Oct 05 11:29:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636722, encodeId=a8b91636e226f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 19 01:29:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313618, encodeId=bf431313618a7, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367656, encodeId=b9d7136e656e7, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380008, encodeId=fb18138000837, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1687672, encodeId=7cef168e672da, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Wed Apr 09 04:29:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759328, encodeId=5b6c1e59328fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 25 13:29:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901131, encodeId=07b6190113191, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 16 11:29:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945585, encodeId=8b841945585d7, content=<a href='/topic/show?id=97c6599160e' target=_blank style='color:#2F92EE;'>#普伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59916, encryptionId=97c6599160e, topicName=普伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat Oct 05 11:29:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636722, encodeId=a8b91636e226f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 19 01:29:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313618, encodeId=bf431313618a7, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367656, encodeId=b9d7136e656e7, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380008, encodeId=fb18138000837, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1687672, encodeId=7cef168e672da, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Wed Apr 09 04:29:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759328, encodeId=5b6c1e59328fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 25 13:29:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901131, encodeId=07b6190113191, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 16 11:29:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945585, encodeId=8b841945585d7, content=<a href='/topic/show?id=97c6599160e' target=_blank style='color:#2F92EE;'>#普伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59916, encryptionId=97c6599160e, topicName=普伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat Oct 05 11:29:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636722, encodeId=a8b91636e226f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 19 01:29:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313618, encodeId=bf431313618a7, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367656, encodeId=b9d7136e656e7, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380008, encodeId=fb18138000837, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1687672, encodeId=7cef168e672da, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Wed Apr 09 04:29:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759328, encodeId=5b6c1e59328fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 25 13:29:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901131, encodeId=07b6190113191, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 16 11:29:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945585, encodeId=8b841945585d7, content=<a href='/topic/show?id=97c6599160e' target=_blank style='color:#2F92EE;'>#普伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59916, encryptionId=97c6599160e, topicName=普伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat Oct 05 11:29:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636722, encodeId=a8b91636e226f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 19 01:29:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313618, encodeId=bf431313618a7, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367656, encodeId=b9d7136e656e7, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380008, encodeId=fb18138000837, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1687672, encodeId=7cef168e672da, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Wed Apr 09 04:29:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759328, encodeId=5b6c1e59328fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Apr 25 13:29:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901131, encodeId=07b6190113191, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Mar 16 11:29:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945585, encodeId=8b841945585d7, content=<a href='/topic/show?id=97c6599160e' target=_blank style='color:#2F92EE;'>#普伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59916, encryptionId=97c6599160e, topicName=普伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sat Oct 05 11:29:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636722, encodeId=a8b91636e226f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 19 01:29:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313618, encodeId=bf431313618a7, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367656, encodeId=b9d7136e656e7, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380008, encodeId=fb18138000837, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Fri Jul 26 08:29:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]